CNC

Business profile & competitive position

Centene Corp. (CNC) sits in the Healthcare sector under the Medical - Healthcare Plans industry. It is described as the nation’s largest managed care company focused on underserved populations, delivering Medicaid, Medicare (Advantage, Prescription Drug Plans, and Supplement products), and commercial Marketplace plans through local brands backed by national infrastructure. For 2025, total revenues reached $194.8 billion, split 57% Medicaid, 21% Commercial, 19% Medicare, and 3% Other. As of December 31, 2025, membership stood at 27.6 million: 12.5 million Medicaid, 5.5 million Marketplace, and 8.1 million stand-alone PDP members. Centene also identifies itself as the largest Medicaid insurer, largest Marketplace insurer, and largest stand-alone PDP provider in the United States.

The scale is real, but the current margin and return figures do not yet point to a strong traditional economic moat. The reported net margin is -2.6% and return on equity is -24.0%. Those negative numbers imply the business generated operating and net losses on a trailing basis, so any pricing power, cost discipline, or membership advantages have not translated into positive shareholder returns recently. Positive operating cash flow of $5.1 billion shows the operations still throw off cash, yet profitability metrics remain under pressure.

Financial posture

Centene’s current market capitalization is $33.6 billion and the stock trades around $68.07, with a 50-day EMA of $66.23 and RSI of 52.8. The P/E ratio is -6.5, which only exists because earnings are negative; a negative P/E is a loss-driven multiple rather than a valuation signal based on normalized profit. The net margin of -2.6% confirms the loss position, while ROE of -24.0% shows the magnitude of the negative equity return on a trailing basis.

Beta is 1.13, meaning the stock has moved slightly more than the broad market on average. There is no long-term debt figure provided in the current data, so leverage cannot be assessed here. What is clear is that the market is pricing Centene at a meaningful discount to prior equity value levels, reflecting the combination of poor trailing earnings and the policy/execution risks tied to government-funded insurance lines.

Strategic priorities & outlook

Centene’s most recent 10-K frames near-term priorities around Medicare-Medicaid integration, Marketplace pricing repair, and state-by-state policy advocacy. Specific operational goals include:

• Refining the Medicare footprint so it overlaps more closely with Medicaid operations, while expanding Dual-Eligible Special Needs Plan (D-SNP) offerings.
• Maintaining an enterprise-level focus on D-SNP products aligned with CMS requirements rolling through 2030.
• Advocating for policies and legislation that preserve affordable Medicaid and Marketplace coverage, as well as cost-effective care for PDP members.
• Implementing 2026 corrective Marketplace pricing actions in states covering 95% of Marketplace membership, and expanding Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states.

Other notable themes include a definitive agreement signed in December 2025 to divest the remaining Magellan Health businesses, which suggests further portfolio simplification. Revenue concentration in Medicaid and Marketplace means the success of these corrective pricing and off-exchange expansion actions is likely to be the main driver of margin trajectory over the next few years.

Macro & geopolitical exposure

Because Centene is a managed care organization primarily funded through Medicaid, Medicare, and ACA Marketplace programs, its top-line and margin outcomes are tightly linked to U.S. healthcare policy and government budgets. The macro and geopolitical exposure relevant to the Medical - Healthcare Plans industry includes:

• Federal and state Medicaid reimbursement changes, including CMS rate decisions, block-grant proposals, and state budget pressures.
• Medicare Advantage and PDP funding rules, star ratings, and annual CMS announcements that reset margins.
• Health reform and Affordable Care Act policy shifts that affect Marketplace enrollment and subsidies.
• Medical cost inflation, especially prescription drug pricing, because the stand-alone PDP business and plan economics are exposed to pharmacy costs.
• Labor cost pressure in healthcare delivery and administrative functions, which affects the “medical loss ratio” and operating margins.

Currency and global trade exposure are generally limited for a U.S.-focused health insurer, although drug importation policies or tariffs on medical supplies could have second-order effects on pharmacy costs.

Recent developments

The most recent headlines around Centene center on third-quarter 2026 earnings and 2027 Marketplace positioning:

• On October 19, 2026, Centene announced it will host its Q3 2026 financial results earnings call (PR Newswire).
• On October 20, 2026, Ambetter Health announced 2027 Marketplace offerings, including enhanced condition-specific coverage options (PR Newswire).
• On October 20, 2026, GuruFocus flagged Centene after a 3.2% gain, noting a GF Value estimate of $78.17 versus a price of $70.81 at that time (gurufocus.com).
• On October 22, 2026, Zacks published a preview titled “Centene to Report Q3 Earnings: Buy, Sell or Hold the Stock?” (zacks.com).

The next scheduled earnings release is October 27, 2026, before the market open, with the current consensus EPS estimate at $0.09578. As of the data snapshot, the stock trades at $68.07, below the October 20 GuruFocus GF Value reference of $78.17.

Earnings behavior & post-earnings drift

Centene has an unusually strong earnings surprise track record over the last eight quarters: it has beaten 7 of 8 times, for an 88% beat rate, with an average surprise of 63.1%. Over the same window, the average 5-day post-earnings drift is +2.83%, classified as an upward drift. That pattern suggests the market often underweights near-term earnings power, or that management’s actual results materially exceed the official consensus.

The last four reports show how noisy the price reaction can be despite the beats:

• July 28, 2026: EPS of $2.51 vs. $1.09 estimate, a 130.3% surprise; the stock fell 3.27% the next day and rose only 0.25% over five days.
• April 28, 2026: EPS of $3.37 vs. $2.23 estimate, a 51.1% surprise; the stock jumped 8.9% the next day and 6.88% over the following five sessions.
• February 6, 2026: EPS of -$1.19 vs. -$1.22007 estimate, a 2.5% surprise; the stock slipped 1.09% the next day but drifted 5.51% higher over five days.
• October 29, 2025: EPS of $0.50 vs. -$0.14475 estimate, a 445.4% surprise; the stock dropped 6.21% the next day and fell 1.34% over five days.

So while the directional drift over a full week has averaged positive, the next-day gap can move against the result. For the October 27, 2026 report, the consensus EPS estimate is only $0.09578, which sets a low formal bar but may also signal underlying expectation that earnings have compressed. The market’s real expectation could be higher than the published estimate given the history of beats.

For traders and investors who want to go further, the full institutional verdict on Centene includes sell-side rating distributions, price-target dispersion, and post-options-flow positioning that can complement the fundamental and earnings-history picture. Reviewing that institutional consensus alongside the numbers above is a sensible next step before forming any view on the stock.